open access
A review of Ciclesonide in COVID-19. Still a long way to go
Affiliations- Pulmonary, Critical Care & Sleep Medicine, Department of Pulmonary Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, India
open access
Abstract
As no definitive therapy or vaccine is yet available for COVID-19, in a desperate attempt repurposed drugs are being explored as an option. A drug repurposing study identified Ciclesonide as a potential candidate. We reviewed the available evidence and clinical trials on the use of Ciclesonide in COVID-19. At present the evidence is limited to a report of three cases. However, five clinical trials are underway, and their results will help in elucidating the role of Ciclesonide in COVID-19.
Abstract
As no definitive therapy or vaccine is yet available for COVID-19, in a desperate attempt repurposed drugs are being explored as an option. A drug repurposing study identified Ciclesonide as a potential candidate. We reviewed the available evidence and clinical trials on the use of Ciclesonide in COVID-19. At present the evidence is limited to a report of three cases. However, five clinical trials are underway, and their results will help in elucidating the role of Ciclesonide in COVID-19.
Keywords
COVID 19; ciclesonide; repurposed drug
About this articleTitle
A review of Ciclesonide in COVID-19. Still a long way to go
Journal
Advances in Respiratory Medicine
Issue
Article type
Letter to the Editor
Pages
79-81
Published online
2020-12-17
DOI
10.5603/ARM.a2020.0173
Pubmed
Bibliographic record
Adv Respir Med 2021;89(1):79-81.
Keywords
COVID 19
ciclesonide
repurposed drug
Authors
Kunal Deokar
Mehul Agarwal
Naveen Dutt
Nishant Chauhan
Ram Niwas
Benhur Joel Shadrach
Gopal Chawla
References (9)- Worldometers. Available online: www.worldometers.info/coronavirus/. [Last accessed at: 15.07.2020].
- Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2020. Available online: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf.[Last accessed at: 13.07.2020].
- Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020; 64(7).
- Matsuyama S, Kawase M, Nao N, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. Available online: www.biorxiv.org/content/10.1101/2020.03.11.987016v1.full.pdf. [Last accessed at: 13.07.2020]. .
- Van den Broeke C, Radu M, Chernoff J, et al. An emerging role for p21-activated kinases (Paks) in viral infections. Trends Cell Biol. 2010; 20(3): 160–169.
- Finnen RL, Roy BB, Zhang H, et al. Analysis of filamentous process induction and nuclear localization properties of the HSV-2 serine/threonine kinase Us3. Virology. 2010; 397(1): 23–33.
- Van den Broeke C, Radu M, Deruelle M, et al. Alphaherpesvirus US3-mediated reorganization of the actin cytoskeleton is mediated by group A p21-activated kinases. Proc Natl Acad Sci U S A. 2009; 106(21): 8707–8712.
- Maruta H, He H. PAK1-blockers: potential therapeutics against COVID-19. Med Drug Discov. 2020; 6: 100039.
- Iwabuchi K, Yoshie K, Kurakami Y, et al. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases. J Infect Chemother. 2020; 26(6): 625–632.